About: Division of Signal Transduction Therapy

An Entity of Type: agent, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute.

Property Value
dbo:abstract
  • The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute. (en)
dbo:affiliation
dbo:budget
  • 2750000.0
dbo:leaderFunction
dbo:numberOfStaff
  • 200 (xsd:nonNegativeInteger)
dbo:parentOrganisation
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 27817581 (xsd:integer)
dbo:wikiPageLength
  • 6047 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 954357769 (xsd:integer)
dbo:wikiPageWikiLink
dbp:affiliations
  • AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica and Pfizer (en)
dbp:budget
  • £2.75 million/year (en)
dbp:formation
  • 1998 (xsd:integer)
dbp:leaderName
  • Dario Alessi, Philip Cohen, Ron Hay (en)
dbp:name
  • Division of Signal Transduction Therapy (en)
dbp:numStaff
  • 200 (xsd:integer)
dbp:parentOrganization
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s disease. Specifically the collaboration aims to target protein kinases and the ubiquitylation system in the development of these therapies. It is one of the largest ever collaborations between the commercial pharmaceutical industry and any academic research institute. (en)
rdfs:label
  • Division of Signal Transduction Therapy (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Division of Signal Transduction Therapy (en)
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License